Although the NDOH guidelines were developed to detect BRCA1/2 P/LP variants, clinically actionable variants in other BC susceptibility genes were found in an additional 5% of participants, supporting the utility of extending testing beyond BRCA1/2 in our setting. This evidence concerns the gene BRCA1 and breast cancer.